# Lung Cancer (Anat, Diag, Path)

## Case Protocol 19 â€“ **Bronchogenic carcinoma**

**Case:**

*A 61-year-old woman presented to her GP with a three-week history of **cough and chest pain**. She had coughed up a small amount of **blood**-**stained** **sputum**. There was no history of fever or night sweats.*

[](data:image/png;base64,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)

*Examination revealed a **thin woman with dyspnoea on mild exertion**. There was decreased expansion of the left side of the chest and the percussion note at the left base was stony dull. Auscultation revealed expiratory rhonchi, and there was no friction rub.*

- Differentials for haemoptysis
    - Provisional: pleural effusion secondary to lung cancer
    - Respiratory causes
        - Neoplastic
            - Primary or secondary (most lung cancers are secondary)
        - Infection
            - Bronchiectasis
            - Pneumonia
            - Lung abscess
            - TB
            - Acute bronchitis
        - Vascular
            - PE
            - Vasculitis (e.g. Goodpastureâ€™s (anti-GBM) or GPA,
    - Cardiac causes
        - CCF (+/- pulmonary oedema)
        - Infective endocarditis (septic embolisms)
    - Note: massive haemoptysis = > 150mL in 24h (enough to compromise airway)
        - Causes
            - Bronchiectasis (rare complication with vessel involvement)
            - Bronchogenic malignancy
            - Vasculitis
            - Trauma
- Approach to history and examination
    - History
        - HOPC: quantify further questions on
            - Symptoms of malignancy, heart failure, respiratory illnesses
            - Cosnitutional: wegihtloss,
        - PMHx: risk factors for lung cancer
            - Previous cancer history, ILD, prior radiation, chronic infections
        - FHx: cancer
        - SHx
            - Tobacco smoking (>20 pack/years = high risk)
            - Air pollution
            - Occupational exposures (asbestos, silica, radioactive gas)
            - Infectious risks: travel, sick contacts, living in a foreign country
    - Examination
        - Signs of smoking use
            - Nicotine staining
            - COPD (emphysema, barrel chest, hyperinflation)
        - Praecordium
            - Signs of atelectasis (decreased air entry) or pleural effusion (stony dull to percussion)
            - Endobronchial tumour
                - Fixed, unilateral monophonic wheeze (does not clear with coughing)
                - Atelectasis
                - Clubbing? (often in context of adenocarcinoma)
        - Signs of compression
            - SVC obstruction (Pembertonâ€™s sign, dilated veins of anterior chest, facial plethora, JVP distension
            - Nerve palsies
                - Phrenic nerve (asymmetric chest expansion)
                - Recurrent laryngeal nerve (hoarse voice)
                - Hornerâ€™s syndrome (miosis, partial ptosis, anhidrosis)
                - Lower trunk of brachial plexus (arm pain and weakness (Klumpkeâ€™s palsy (claw hand))
        - Signs of paraneoplastic syndrome
            - Common in both NSCLC and SCLC
                - Cachexia (increased metabolic rate)
                - Thrombocytosis and DIC
                - Dermatomyositis, acanthosis nigricans
            - More common in NSCLC
                - Hypercalcaemia
                - Hypertrophic pulmonary osteoarthropathy (HPOA)
                    - Swollen painful joints, clubbings of fingers and bones (due to periosteal proliferation)
            - More common in SCLC
                - SIADH (confusion, nausea and vomiting)
                - Cushingâ€™s syndrome
                    - Fat redistribution (buffalo hump, moon facies)
                    - Purple abdominal striae
                    - Diabetes mellitus
                    - Osteoporosis
                    - Poor wound healing
                    - Muscle atrophy
                - Lambert-Eaton syndrome (motor weakness)
                    - Autoimmune disorder with antibodies against the presynaptic Ca channels
                        - Results in decreased ACh release
                        - Strongly associated with paraneoplastic syndromes
                    - Weakness improves with repetition and exercise
        - Signs of metastases
            - Bone pain
            - Hepatomegaly, jaundice
            - Seizures, focal neurological deficits
- Risk factors for lung cancer
    - Non-modifiable
        - PMHx
            - ILD
            - Chronic infections (e.g. TB, HIV)
            - Prior radiation (e.g. lymphoma, breast cancer)
        - FHx in a 1st degree relative
        - Older age
    - Modifiable
        - Tobacco smoking (>20 pack years = high risk)
        - Air pollution
        - Occupational exposures
            - Asbestos, silica, radioactive material
- Investigative approach to lung cancer
    - Principal diagnostic investigations
        - Sputum MCS, cytology, AFB
            - Cytology to detect neoplastic cells (often only if central location - SCLC common)
            - Macroscopic appearance (blood)
            - MCS and AFB to rule out infective causes
        - Imaging
            - CXR
                - Detect nodules (coin lesions)
                - Atelectasis (secondary to airway obstruction by endobronchial tumour)
                - Pleural effusion
                - Hilar and mediastinal lymphadenopathy
                - Secondary pneumonia
            - CT chest, neck and upper abdomen with contrast
                - Location, size, extent of lesion and any distant metastases
        - Procedural
            - Pleurocentesis
                - Cytology, LDH and protein (with serum LDH and protein)
                    - Determine if effusion is transudate or exudate
                    - Cytology for neoplastic cells
            - Tissue biopsy
                - Bronchoscopy with biopsy +/- lavage
                    - Useful for central lesions (not peripheral)
                    - Can be inserted up to the secondary branches of the bronchial tree
                - Percutaneous CT-guided needle biopsy
                    - Useful for peripheral lesions
    - Ancillary investigations
        - Bedside
            - Pulse oximetry
            - ECG (investigate CCF, PE)
            - Spirometry
                - Useful to guide investigation and management
                    - Suitability for pneumonectomy (FEV1 > 1.5L)
                    - Prior to percutaneous CT-guided biopsy (FEV > 1L)
            - Blood gas (acidosis, hypoxia)
        - Labs
            - FBC (anaemia of chronic disease, leukocytosis (infection))
            - UEC (baseline for imaging and treatment, hypoNa) â€”> Eucs : sodium - paraneoplastic - high adh ,
            - CMP (hypercalcaemia of malignancy) papraneoplastplatic neoplastic syndrome,
            - LFT (metastases)
            - Coagulation (bleeding risk)
            - CRP (infection, inflammation)
            - Other tests for paraneoplastic syndromes (if indicated)
                - ACTH and ADH (elevated in SCLC)
                - PTHrP (SCLC)
        - Imaging
            - Staging PET
                - More sensitive for detecting distant metastases
            - Can consider CT abdomen, bone scan
            - MRI brain (metastases)
        - Sputum:
            - Acid fast bacilli ?
            - Cryptococcus
            - Cytology
- Histopathological findings in lung cancer
    - Non-small cell lung cancer (75-85%)
        - Adenocarcinoma (35%)
            - Significant proportion in non-smokers
            - Prognosis determined by grade, stage and immunohistochemistry (number of therapeutic targets)
                - 5-year survival (stage 1: 50%, stage 4: 5%)
                - Tends to be most slow growing
            - Location: peripheral
            - Histopathology
                - Abundant cytoplasm
                - Derived of glandular mucin producing cells
                    - Can be classified as acinar, papillary, mucinous, solid-type
        - Squamous cell lung cancer (30%)
            - Strong correlation with smoking
            - Prognosis determined by grade, stage and immunohistochemistry (number of therapeutic targets)
                - 5-year survival (stage 1: 50%, stage 4: 5%)
            - Location: central
            - Histopathology
                - Abundant cytoplasm
                - Well differentiated
                    - Keratin pearls
                    - Intercellular bridges (desmosomes)
                - Derived from epidermoid cells
        - Large cell lung cancer (5-10%)
            - Strong correlation with smoking
            - Prognosis determined by grade, stage and immunohistochemistry (number of therapeutic targets)
                - Tends to be more rapid growing, poor prognosis
            - Location: central
            - Histopathology
                - Abundant cytoplasm
                - Anaplastic and undifferentiated cells
                    - Diagnosis of exclusion
    - Small-cell lung cancer (15-25%)
        - Strong correlation with smoking
        - Worst prognosis overall
            - Large proportion have extrathoracic metastases at diagnosis
            - Frequently associated with paraneoplastic syndromes
            - 5-year survival
                - Stage 1: 10%
                - Stage 4: 1-2%
        - Location: central
        - Histopathology
            - Arises from neuroendocrine cells (enterochromaffin cells) which often produce hormones or enzymes (paraneoplastic)
            - Oat cells
                - Scant cytoplasm, small hyperchromatic nuclei with fine granular chromatin pattern
                - Indistinct nucleoli and numerous mitoses
            - Ill-defined cell borders
    - Other: carcinoid, lymphoma
- Natural history and prognosis of lung cancer
    - Prognosis dependent on:
        - Patient factors
            - Age
            - Comorbidities
            - Functional status (ECOG)
                - 0 = fully active
                - 1 = limited in physical strenuous activity, otherwise independent
                - 2 = independent but unable to work
                - 3 = limited self care, largely sedentary
                - 4 = completely disabled, dependent, unable to perform self care
                - 5 = dead
        - Tumour factors
            - Type (including receptor expression)
            - Grading
            - Staging
- Complications of lung cancer
    - Local invasion
        - Invasion of pleura and chest wall
        - Invasion into neurovascular structures
        - Secondary pneumonia- endobronchial obstruction
        - Atelectasis
        - pleural effusion/ pnuemothorax- peripherpal - really vascularised - can have leakage â€”> pleural effusion
            - If its peripheral it can pop
        - Mass effects:
    - Metastases
        - Liver, bone, brain
    - Systemic complications
        - Paraneoplastic syndromes
            - DIC and VTE (hypercoagulability) - cancers highly coaguble
            - HOPA - Hypertrophic pulmonary osteoarthropathy (HPOA),
            - PTHrP (hypercalcaemia)
            - Lambert-Eaton syndrome
- Likely causes of death in lung cancer
    - Related to local effects
        - Pneumonia and sepsis
            - cancer goes into bronchus â€”> blcoks it off â€”> mucin baack flow â€”> penunonia __. backs it up sepsis
        - Respiratory failure (massive pleural effusion, bronchiectasis, phrenic nerve palsy)
        - SVC obstruction
    - Related to metastatic disease â†’ multiorgan failure
    - Related to systemic effects
        - DIC
        - VTE and PE
        - Arrhythmias (hyperK)
        - HypoNa

### Memorandum: Lung Cancer (Anatomy)

**Case:**

*A 60-year-old male presents withÂ **productive cough**Â and reports havingÂ **blood**Â in his sputum, as well asÂ **hoarseness**. He has beenÂ **smoking for 40 years**. On auscultation, there wasÂ **dullness to percussion**Â withÂ **decreased air entry**Â on the left upper lobe. He also reports recentÂ **difficulty in breathing**Â andÂ **difficulty with phonation.***

- Hornerâ€™s syndrome in lung cancer
    - Hornerâ€™s syndrome is a clinical triad caused by disruption of sympathetic supply to the head and neck
        - Signs: ptosis (partial - superior tarsal muscle), miosis (loss of dilator pupillae innervation and unopposed sphincter pupillae), anhidrosis (SNS supply to sweat glands)
        - Course
            - 1st order neurons from brainstem â€”> synapse in upper thoracic spinal cord (T1)
            - 2nd order neurons synapse at superior (C1-4), middle (C5-6) or inferior (C7-8) cervical ganglia
                - Sometimes inferior ganglion can fuse with T1 ganglion to form stellate ganglion
            - 3rd order neurons to target site
    - Stellate ganglion and superior sympathetic inputs can be disrupted by apical lung tumour
- Presentation of apical lung tumours
    - Also known as Pancoast tumours (or superior sulcus tumours)
    - Common signs and symptoms to all lung cancers
        - Weight loss, night sweats, fever
        - Cough, haemoptysis, chest pain, dyspnoea
    - Signs and symptoms related to regional invasion/compression
        - Hornerâ€™s syndrome
        - Phrenic nerve invasion (diaphragm hemiparesis)
        - Recurrent laryngeal nerve palsy (dysphonia, bovine cough)
        - SVC obstruction (facial plethora, raised JVP, distended anterior chest and neck veins)
        - Brachial plexus (paraesthesias, Klumpkeâ€™s palsy)
- Bronchoscopy findings
    - Firm, irregular, intraluminal mass
        - May look grey or white
        - +/- active bleeding (erythema, active haemorrhage)
        - +/- fungation and central necrosis
        - +/- demonstration of invasive or compressive growth (bronchial narrowing)
- Laryngoscopy findings for hoarseness
    - Hoarseness
        - Due to involvement of the ipsilateral recurrent laryngeal nerve (innervates all intrinsic laryngeal muscles except cricothyroid (external branch of superior laryngeal)
            - Dysphonia as vocal cords unable to vibrate together effectively
    - Appearance on laryngoscopy
        - Vocal cords appear asymmetric
            - Normal cord â†’ rests near the midline
            - Abnormal cord â†’ deviated from the midline (due to atrophy or poor tone)
                - During phonation, the cord would vibrate less (vocalis muscle unable to contract taut)

Anatomy

- Phrenic nerve
    - Origin: anterior rami of C3, C4, C5
    - Course
        - Arises on the lateral edge of the anterior scalene, passes anterior
        - Enters thorax via superior inlet (passes between subclavian artery (posterior) and vein (anterior))
        - Right
            - Descends through mediastinum posterior to SVC and then along pericardium of R atrium
        - Left
            - Crosses anterior to aortic arch and descends through mediastinum along pericardium of left ventricle
    - Function
        - Motor: innervates diaphragm
        - Sensory: central part of diaphragm, pericardium, mediastinal part of parietal pleura
- Anatomy of speech
    - Vagus nerve innervates all intrinsic muscles of the larynx
        - External branch of superior laryngeal nerve â†’ cricothyroid muscle
        - Inferior laryngeal nerve (branch of recurrent laryngeal) â†’ all others
    - Function
        - Cricothyroid
            - Tenses vocal ligaments
        - Thyroarytenoid
            - Relaxes vocal ligaments (shortens folds by drawing arytenoids to the cartilage)
        - Lateral cricoarytenoid, transverse and oblique arytenoids
            - Adduct vocal folds
        - Posterior cricoarytenoid
            - Abducts vocal folds

### Memorandum: Lung Cancer (D)

*A 60-year-old male presents withÂ **productive cough**Â and reports havingÂ **blood**Â in his sputum, as well asÂ **hoarseness**. He has beenÂ **smoking for 40 years**. On auscultation, there wasÂ **dullness to percussion**Â withÂ **decreased air entry**Â on the left upper lobe. He also reports recentÂ **difficulty in breathing**Â andÂ **difficulty with phonation.***

- Causes of solitary pulmonary nodules on CXR?
    - Neoplastic
        - Benign - pulmonary hamartoma
        - Malignant
            - Primary - NSCLC, SCLC, carcinoid
            - Secondary
            - Lymphadenopathy (including lymphoma)
    - Infectious
        - TB (Ghon focus)
        - Abscess
        - Hydatid cyst (echinococcis))
    - Inflammatory (granulomas - sarcoidosis, rheumatoid nodule)
    - Congenital (bronchogenic cyst)
    - Vascular (AVM, infarction)
- Method of bronchoscopy
    - An endoscopic procedure which allows visualisation of the bronchial tree and the obtaining of tissue samples
        - Uses a flexible fibreoptic bronchoscope
            - Can use rigid scope with GA and insertion through mouth
        - Scope is passed via the nose or mouth, through the vocal cords and trachea, up to the lobar bronchi (occasionally segmental may be seen)
- Complications of bronchoscopy
    - Bleeding
    - Infection
    - Perforation
    - Vocal cord injury
    - Laryngospasm
    - Pneumothorax
    - General anaesthesia risks
- Types of sampling specimens
    - Bronchoalveolar lavage
        - Instillation and aspiration of around 5-20mL of sterile saline mixed with bronchial secretions into bronchial trap
        - Aspirate of fluid is collected for cytological analysis
    - Endobronchial brushings
        - Cells collected for cytology
    - Tissue biopsy
        - Allows for histopathological analysis (FNA, forceps biopsy, core biopsy)

### Memorandum: Lung Cancer (Path)

**Case:** *A 63-year-old male presents with two-week history haemoptysis and a 2-month history of weight loss. He has smoked 2 packs of cigarettes a day for 45 years. Examination reveals tachypnoea, pleural effusion and a temperature*

*OR*

*a 40-year-old female, non-smoker, presents with fever, weight loss, lethargy. CXR shows mediastinal widening and lung collapse. Later they tell you they found adenocarcinoma at left bronchus with enlarged mediastinal lymph nodes*

- Haemoptysis in pneumonia
    - Can be present in pneumonia if the infection invades a blood vessel or following abscess development
- Pneumonia and cancer
    - Obstruction of central airways by tumour or extrinsic compression â†’ atelectasis, impaired mucociliary clearance of secretions
        - Accumulation of secretions, pneumonitis and increased infection risk
        - E.g. H. influenzae, K. pneumoniae, P. aeruginosa, S. aureus
- Important tumour markers in lung cancer
    - Note: tumour markers are most relevant for adenocarcinoma work-up
    - EGFR tyrosine kinase mutation
        - More common in non-smokers, women and/or East Asian population
        - Better prognosis
            - Responsive to EGFR tyrosine kinase inhibitors (gefitinib)
    - ALK (anaplastic lymphoma kinase) translocations â†’ form fusion proto-oncogenes
        - More common in young, non-smokers
        - Responsive to ALK tyrosine kinase inhibitors) (crizotinib)
    - ROS1 translocation
        - More common in young non-smokers
        - Responsive to ROS1 tyrosine kinase inhibitors
    - PD-L1 (expressed by tumour cells to downregulate T-cell response)
        - Immunotherapy neutralises these PD-L1 ligands to improve T-cell antitumour activity
- Staging investigations in lung cancer
    - Grading: no specific grading system
        - Based on degree of histopathological differentiation (well â†’ poor)
    - Staging
        - TNM system (NSCLC)
            - Tumour: based on size and invasivenes
                - Tis (in situ)
                - T1 (â‰¤3cm)
                - T2 (3-5cm) or invasive into the main bronchus or other structures; or associated with atelectasis
                - T3 (>5cm; â‰¤7cm) or separate nodules in the same lobe or invasion of certain structures e.g. chest wall
                - T4 (>7cm) or seaparate nodules in different lobes or invasion of certain structures e.g. diaphragm
            - Nodes: based on regional nodal involvement
                - N0 no nodal involvement
                - N1 involvement of ipsilateral peribronchial, hilar or intrapulmonary nodes
                - N2 involvement of ipsilateral mediastinal and/or subcarinal lymph nodes
                - N3 involvement in contralateral nodes
            - Metastases
                - M0 - none
                - M1 - distant
        - Summary
            - Stage 0 = Tis
            - Stage 1 = T1/2, N0, M0
            - Stage 2 = T3/N0/M0 OR T<3,N1,M0
            - Stage 3 = T up to 4, N up to 3, M0
            - Stage 4 = M1
        - Note: SCLC staging depends on whether the disease is limited (within one radiotherapy field) or extensive
            - Can use TNM system but less relevant
- Treatment options in lung cancer
    - NSCLC
        - Early stage (1,2)
            - Surgery
                - Coin lesion â†’ lobectomy or pneumectomy + lymph node resection
                - Endobronchial â†’ sleeve resection (ends of bronchus rejoined and remaining lobes reattached)
            - Adjuvant radiotherapy and/or chemotherapy
        - Advanced
            - Combined radiotherapy and or chemotherapy
                - Surgery if respectable
            - Consider involvement of palliative care
        - Targeted immunotherapy may have a role
    - SCLC
        - Surgery generally of limited benefit and not considered
        - Chemotherapy and radiotherapy
        - Consider involvement of palliative care
    - Monitoring
        - Curative intent: monitoring every 3 months for 1 year, then every 6 months to 5 years
        - Non-curative intent: varies by goals of care
- Relationship between lung cancer and clinical signs
    - Local
        - Tachypnoea: reduced area of ventilation (atelectasis, airway obstruction), pneumonia, pain
        - Haemoptysis: invasion of cancer into a pulmonary vessel
        - Chronic cough: irritation of juxtacapillary receptors in respiratory epithelium by cancer and surrounding inflammation
        - Fever: pneumonia or constitutional cancer symptoms (inflammatory mediators)
        - Dyspnoea: due to airway obstruction +/- distal atelectasis, underlying COPD, new pneumonia or pleural effusion
        - Fixed inspiratory wheeze: bronchogenic carcinoma partially occluding airway
    - Regional
        - Hoarseness: invasion of recurrent laryngeal nerve or direct vocal cord involvement
        - Chest pain: invasion of parietal pleura or chest wall
        - Effusion: involvement of pleura in inflammation and increased vascular permeability or damage â†’ exudation
        - Clubbing: chronic hypoxia
        - Signs of SVC obstruction
        - Supraclavicular lymphadenopathy
    - Metastases
        - Cachexia and weight loss (hypercatabolic state)
        - SIADH
        - Cushing syndrome (ectopic ACTH release)
        - Abdominal pain, bone pain, renal calculi, mood disorders (hypercalcaemia)
            - PTHrP?
- How does lung cancer spread
    - Lymphatics
        - Intrapulmonary â†’ bronchopulmonary (hilar) â†’ tracheobronchial â†’ paratracheal â†’ bronchomediastinal trunk â†’ R lymphatic duct OR thoracic duct
        - May involve supraclavicular or scalene nodes
    - Haematological
        - Bone, brain, liver
    - Direct invasion into surrounding structures (e.g. diaphragm, chest wall)
- Interpret spirometry
    - Normal FEV1/FVC = 75-80%
    - Obstructive: FEV1/FVC < LLN (<70%)
        - Flow rate is very low in relation to total lung volume due to resistance to flow (obstruction) (FEV1 low)
        - TLC is normal but expiration ends prematurely due to airway closure (increased smooth muscle role - asthma; loss of radial traction - emphysema)
    - Restrictive: FEV1/FVC = normal or increased
        - Total volume exhaled and flow rate reduced
        - Limited inspiration due to reduced lung or chest wall compliance
            - Weakness of inspiratory muscles
    
    ![paste-07b216a6a15b9ebe20d6eac2205c438f241e2c16.jpg](Lung%20Cancer%20(Anat,%20Diag,%20Path)%201300acf2446a81888acfcc2aa419c479/paste-07b216a6a15b9ebe20d6eac2205c438f241e2c16.jpg)
    
- How would COPD affect surgical chances?
    - Decreased pulmonary function increases the risk of post-operative pulmonary complications and decreased chance of successful outcome after surgery (ASA 4, high risk)
        - Surgery has high physiological stress demands â†’ massive increase in O2 requirements
        - May require mechanical ventilation post-operative and high monitoring requirements
    - Continued smoking increases risk of:
        - DVT
        - Infection (impaired leukocyte function)
        - Impaired healing due to vasoconstriction
    - To improve outcomes
        - Manage COPD perioperatively
        - Advocate smoking cessation
        - Consider regional anaesthesia > GA
- SCLC - features and autopsy findings
    - Pathology
        - Pale grey, centrally located masses
            - Extension into lung parenchyma and early involvement of hilar and mediastinal nodes
        - Tumour cells have scant cytoplasm and finely granular chromatin
            - Frequently see mitotic figures
    
    ![Screenshot 2023-11-08 at 10.47.31â€¯pm.png](Lung%20Cancer%20(Anat,%20Diag,%20Path)%201300acf2446a81888acfcc2aa419c479/Screenshot_2023-11-08_at_10.47.31_pm.png)
    
- Paraneoplastic effects of SCLC
    - **Hypercalcaemia (PTHrP release) (also in SCC)**
    - Cushing syndrome (ectopic ACTH)
    - SIADH (ectopic ADH)
    - Neuromuscular syndromes
        - Myasthenic syndrome, peripheral neuropathy, polymyositis
    - Clubbing + hypertrophy pulmonary osteoarthropathy
    - **Coagulation abnormalities (also in adenocarcinomas)**
        - Migratory thrombophlebitis, NBTE, DIC
- Pathogenesis of lung cancer (and smoking)
    - Stepwise accumulation of genetic abnormalities which follow a predictable sequence
        - Early inactivation of putative TSGs (e.g. 3p)
        - Late TP53 mutations or KRAS activations
    - Smoking greatly increases the risk (90% in active or past smokers)
        - Genetic factors through P450 enzyme system may have a role in increasing the metabolic activation of procarcinogens in cigarette smoke to full carcinogens
        - Result in epithelial hyperplasia â†’ metaplasia â†’ dysplasia and neoplasia
    - Genetic factors can play a role
        - EGFR mutations (Eastern women) or ALK tyrosine kinase genes and c-MET kinase amplifications
            - Targeted with immunotherapy